awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q45893661-3DCA64AC-CC61-4550-B011-EB451C4B835D
Q45893661-3DCA64AC-CC61-4550-B011-EB451C4B835D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q45893661-3DCA64AC-CC61-4550-B011-EB451C4B835D
Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective.
P2860
Q45893661-3DCA64AC-CC61-4550-B011-EB451C4B835D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q45893661-3DCA64AC-CC61-4550-B011-EB451C4B835D
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
bbd35c85b2ed5ab27d7e4de8f6e4b58e860469aa
P2860
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study.